Data from this abstract
Imugene (ASX: IMU) has unveiled “impressive” pre-clinical in vivo anti-tumour responses using its onCARlytics technology in combination with Eureka Therapeutics’ Artemis’ T cell platform on models with liver cancer.
will be presented in full at ASGCT on May 16th-20th
Data from this abstractImugene (ASX: IMU) has unveiled...
-
- There are more pages in this discussion • 11,510 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $405.3M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.5¢ | 5.3¢ | $817.0K | 15.17M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 4719788 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 453183 | 5 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |